CALA News Alert Calithera Biosciences Inc. (CALA) 20.20 01/01/2015
Post# of 64086
Posted On: 01/01/2015 3:57:47 PM
Calithera Biosciences Inc. (CALA) 20.20 $CALA
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 12:05PM CST
FATE: 5.03 (-0.62), SIBC: 20.72 (+5.36), FUR: 15.59 (-2.32), DRAM: 1.70 (-0.23), NRX: 13.35 (+8.70), MEIL: 1.36 (+0.35), MIG: 8.46 (+1.33), BCLI: 4.76 (+0.88), ABAC: 1.73 (-0.18), GBR: 1.51 (+0.23), NDRM: 14.04 (-4.10), RCMT: 7.00 (-1.55), AGRX: 6.14 (-0.56), REN: 1.32 (+0.28), KEG: 1.67 (-0.19), LIME: 2.93 (+0.52), CALA: 20.20 (+1.89), CJJD: 2.90 (-0.25), CBMG: 12.91 (+1.39), GNI: 13.90 (-1.90)
Calithera (CALA) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 26, 8:51AM CST
Calithera (CALA) Shares March Higher, Can It Continue?
CALA: 20.20 (+1.89)
Profit taking continues for Calithera Bio
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 10:38AM CST
CALA: 20.20 (+1.89)
Calithera Biosciences Slumps: CALA Tanks 10.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 7:50AM CST
Calithera Biosciences (CALA) fell by over 10% in the last trading session amid huge volumes, reversing its recent uptrend, as the stock is now up nearly 185% in the past one month.
LCI: 42.88 (-0.65), SCMP: 14.28 (+0.39), CALA: 20.20 (+1.89), IG: 8.80 (-0.12)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 8:12AM CST
FRO: 2.51 (-0.08), TLM: 7.83 (unch), SPHS: 0.54 (+0.03), HGSH: 4.29 (-0.12), SN: 9.29 (-0.04), NBG: 1.79 (unch), AXAS: 2.94 (unch), RVBD: 20.41 (unch), OPK: 9.99 (+0.14), ANTH: 1.58 (-0.03), ONVO: 7.25 (-0.41), KEG: 1.67 (-0.19), CALA: 20.20 (+1.89), XCO: 2.17 (+0.07), CRUS: 23.57 (+0.02), ARCP: 9.05 (-0.06)
Calithera Biosciences, Inc. (CALA) in Focus: Stock Soars 29.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 8:18AM CST
Calithera Biosciences, Inc. (CALA) was a big mover last session, as the company saw its shares rise by nearly 30% on the day.
LCI: 42.88 (-0.65), SCMP: 14.28 (+0.39), CALA: 20.20 (+1.89), IG: 8.80 (-0.12)
Calithera Presents Novel Pharmacodynamic Assay Data Confirming Glutaminase Inhibition in Tumor Biopsy Samples From Patients Treated With CB-839
GlobeNewswire - Wed Dec 10, 12:00PM CST
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer agents, today announced results of studies with primary human breast tumors that support glutaminase as a potential target in triple negative breast cancer (TNBC). Using a novel pharmacodynamic assay designed to measure the extent of glutaminase inhibition in a single post-dose tumor biopsy sample, significant glutaminase inhibition was observed following oral administration of CB-839. These data were presented during the San Antonio Breast Cancer Symposium in San Antonio, Texas. Calithera is developing CB-839, a potent, selective and orally bioavailable glutaminase inhibitor that is currently in Phase I clinical trials in solid and hematological malignancies.
CALA: 20.20 (+1.89)
Calithera up again after ASH presentation
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 11:08AM CST
CALA: 20.20 (+1.89)
Calithera Biosciences Gains Exclusive, Worldwide License to Mars Symbioscience's Arginase Inhibitors
GlobeNewswire - Tue Dec 09, 8:12AM CST
Calithera Biosciences, Inc. (Nasdaq:CALA) announced today the signing of an exclusive global license agreement with Mars Symbioscience ("Symbioscience"
, a division of Mars, Incorporated, granting Calithera rights to research, develop and commercialize Symbioscience's portfolio of arginase inhibitors, discovered as part of Mars' cocoa flavanol research program, for use in human healthcare. Symbioscience's preclinical arginase inhibitor program will enhance Calithera's efforts to submit an Investigational New Drug application for an arginase inhibitor with the FDA for the treatment of cancer near the end of 2015.
CALA: 20.20 (+1.89)
Calithera up after ASH presentation
Seeking Alpha - at Seeking Alpha - Mon Dec 08, 2:45PM CST
CALA: 20.20 (+1.89)
Calithera Presents Preclinical Study Findings for CB-839 at the 56th American Society of Hematology Annual Meeting
GlobeNewswire - Mon Dec 08, 11:00AM CST
-Potential Biomarkers of Response to CB-839 Identified in Myeloma Cells
CALA: 20.20 (+1.89)
Calithera Biosciences hires H. Ward Wolff to board
M2 - Wed Dec 03, 7:06AM CST
Pharmaceutical company Calithera Biosciences (NasdaqGS:CALA) reported on Tuesday the addition of H. Ward Wolff to its board of directors as well as chair of its Audit Committee.
PTLA: 28.32 (-0.24), CALA: 20.20 (+1.89), SGMO: 15.21 (+0.39)
Calithera Biosciences Appoints H. Ward Wolff to Board of Directors
GlobeNewswire - Tue Dec 02, 4:00PM CST
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, announced today the appointment of H. Ward Wolff to the company's Board of Directors, where he will chair the company's Audit Committee. Mr. Wolff is currently Executive Vice President and Chief Financial Officer of Sangamo BioSciences, Inc.
CALA: 20.20 (+1.89), SGMO: 15.21 (+0.39)
Calithera Biosciences net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 10:49AM CST
CALA: 20.20 (+1.89)
Calithera Biosciences net loss of $5.24M
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 8:11AM CST
CALA: 20.20 (+1.89)
Calithera Reports Financial Results for the Fiscal Quarter Ended September 30, 2014
GlobeNewswire - Fri Nov 14, 7:30AM CST
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, announced today its financial results for the fiscal quarter ended September 30, 2014.
CALA: 20.20 (+1.89)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 12:05PM CST
FATE: 5.03 (-0.62), SIBC: 20.72 (+5.36), FUR: 15.59 (-2.32), DRAM: 1.70 (-0.23), NRX: 13.35 (+8.70), MEIL: 1.36 (+0.35), MIG: 8.46 (+1.33), BCLI: 4.76 (+0.88), ABAC: 1.73 (-0.18), GBR: 1.51 (+0.23), NDRM: 14.04 (-4.10), RCMT: 7.00 (-1.55), AGRX: 6.14 (-0.56), REN: 1.32 (+0.28), KEG: 1.67 (-0.19), LIME: 2.93 (+0.52), CALA: 20.20 (+1.89), CJJD: 2.90 (-0.25), CBMG: 12.91 (+1.39), GNI: 13.90 (-1.90)
Calithera (CALA) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 26, 8:51AM CST
Calithera (CALA) Shares March Higher, Can It Continue?
CALA: 20.20 (+1.89)
Profit taking continues for Calithera Bio
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 10:38AM CST
CALA: 20.20 (+1.89)
Calithera Biosciences Slumps: CALA Tanks 10.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 7:50AM CST
Calithera Biosciences (CALA) fell by over 10% in the last trading session amid huge volumes, reversing its recent uptrend, as the stock is now up nearly 185% in the past one month.
LCI: 42.88 (-0.65), SCMP: 14.28 (+0.39), CALA: 20.20 (+1.89), IG: 8.80 (-0.12)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 8:12AM CST
FRO: 2.51 (-0.08), TLM: 7.83 (unch), SPHS: 0.54 (+0.03), HGSH: 4.29 (-0.12), SN: 9.29 (-0.04), NBG: 1.79 (unch), AXAS: 2.94 (unch), RVBD: 20.41 (unch), OPK: 9.99 (+0.14), ANTH: 1.58 (-0.03), ONVO: 7.25 (-0.41), KEG: 1.67 (-0.19), CALA: 20.20 (+1.89), XCO: 2.17 (+0.07), CRUS: 23.57 (+0.02), ARCP: 9.05 (-0.06)
Calithera Biosciences, Inc. (CALA) in Focus: Stock Soars 29.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 8:18AM CST
Calithera Biosciences, Inc. (CALA) was a big mover last session, as the company saw its shares rise by nearly 30% on the day.
LCI: 42.88 (-0.65), SCMP: 14.28 (+0.39), CALA: 20.20 (+1.89), IG: 8.80 (-0.12)
Calithera Presents Novel Pharmacodynamic Assay Data Confirming Glutaminase Inhibition in Tumor Biopsy Samples From Patients Treated With CB-839
GlobeNewswire - Wed Dec 10, 12:00PM CST
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer agents, today announced results of studies with primary human breast tumors that support glutaminase as a potential target in triple negative breast cancer (TNBC). Using a novel pharmacodynamic assay designed to measure the extent of glutaminase inhibition in a single post-dose tumor biopsy sample, significant glutaminase inhibition was observed following oral administration of CB-839. These data were presented during the San Antonio Breast Cancer Symposium in San Antonio, Texas. Calithera is developing CB-839, a potent, selective and orally bioavailable glutaminase inhibitor that is currently in Phase I clinical trials in solid and hematological malignancies.
CALA: 20.20 (+1.89)
Calithera up again after ASH presentation
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 11:08AM CST
CALA: 20.20 (+1.89)
Calithera Biosciences Gains Exclusive, Worldwide License to Mars Symbioscience's Arginase Inhibitors
GlobeNewswire - Tue Dec 09, 8:12AM CST
Calithera Biosciences, Inc. (Nasdaq:CALA) announced today the signing of an exclusive global license agreement with Mars Symbioscience ("Symbioscience"
, a division of Mars, Incorporated, granting Calithera rights to research, develop and commercialize Symbioscience's portfolio of arginase inhibitors, discovered as part of Mars' cocoa flavanol research program, for use in human healthcare. Symbioscience's preclinical arginase inhibitor program will enhance Calithera's efforts to submit an Investigational New Drug application for an arginase inhibitor with the FDA for the treatment of cancer near the end of 2015. CALA: 20.20 (+1.89)
Calithera up after ASH presentation
Seeking Alpha - at Seeking Alpha - Mon Dec 08, 2:45PM CST
CALA: 20.20 (+1.89)
Calithera Presents Preclinical Study Findings for CB-839 at the 56th American Society of Hematology Annual Meeting
GlobeNewswire - Mon Dec 08, 11:00AM CST
-Potential Biomarkers of Response to CB-839 Identified in Myeloma Cells
CALA: 20.20 (+1.89)
Calithera Biosciences hires H. Ward Wolff to board
M2 - Wed Dec 03, 7:06AM CST
Pharmaceutical company Calithera Biosciences (NasdaqGS:CALA) reported on Tuesday the addition of H. Ward Wolff to its board of directors as well as chair of its Audit Committee.
PTLA: 28.32 (-0.24), CALA: 20.20 (+1.89), SGMO: 15.21 (+0.39)
Calithera Biosciences Appoints H. Ward Wolff to Board of Directors
GlobeNewswire - Tue Dec 02, 4:00PM CST
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, announced today the appointment of H. Ward Wolff to the company's Board of Directors, where he will chair the company's Audit Committee. Mr. Wolff is currently Executive Vice President and Chief Financial Officer of Sangamo BioSciences, Inc.
CALA: 20.20 (+1.89), SGMO: 15.21 (+0.39)
Calithera Biosciences net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 10:49AM CST
CALA: 20.20 (+1.89)
Calithera Biosciences net loss of $5.24M
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 8:11AM CST
CALA: 20.20 (+1.89)
Calithera Reports Financial Results for the Fiscal Quarter Ended September 30, 2014
GlobeNewswire - Fri Nov 14, 7:30AM CST
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, announced today its financial results for the fiscal quarter ended September 30, 2014.
CALA: 20.20 (+1.89)
(0)
(0)Scroll down for more posts ▼